Efficacy and Safety of Tyrosine Kinase Inhibitors Alone or Combination with Programmed Death-1 Inhibitors in Treating of Hepatitis C-Related Hepatocellular Carcinoma.
Journal of hepatocellular carcinoma（2023）
摘要
The patients having HCV-related uHCC after being treated with the TKI and PD-1 inhibitor combination therapy exhibited a better prognosis and manageable toxicity compared to the patients who underwent TKI monotherapy.
更多查看译文
关键词
hepatitis C virus,hepatitis C virus reactivation,hepatocellular carcinoma,programmed death-1 inhibitor,tyrosine kinase inhibitor
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要